Oct 14, 2026 08:46AM
Sep 24, 2026 08:05AM
Sep 24, 2026 08:05AM
Sep 3, 2026 08:06AM
Sep 3, 2026 08:05AM
Aug 21, 2026 04:13PM
Aug 14, 2026 08:05AM Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
Aug 13, 2026 04:06PM
Aug 13, 2026 04:05PM
Aug 12, 2026 09:35AM
Aug 12, 2026 09:30AM
Jul 27, 2026 08:06AM
Jul 27, 2026 08:05AM
Jun 30, 2026 08:06AM Aptevo gets $1.5M grant to advance APVO451 cancer therapy
Jun 30, 2026 08:05AM
May 28, 2026 08:05AM
May 28, 2026 08:05AM
May 27, 2026 08:05AM
May 27, 2026 08:05AM
May 13, 2026 08:07AM
May 13, 2026 08:05AM Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
May 6, 2026 08:10AM
May 6, 2026 08:05AM
Mar 26, 2026 08:05AM
Mar 19, 2026 08:05AM
Mar 10, 2026 08:21AM
Mar 10, 2026 08:05AM
Feb 3, 2026 08:06AM Aptevo Therapeutics announces CEO transition effective April
Feb 3, 2026 08:05AM
Jan 28, 2026 04:23PM
Jan 9, 2026 08:05AM
Jan 9, 2026 08:05AM
Dec 26, 2025 08:05AM
Dec 26, 2025 08:05AM
Dec 9, 2025 08:07AM Aptevo reports no cytokine release syndrome in AML drug trial
Dec 9, 2025 08:05AM
Nov 10, 2025 08:05AM
Nov 10, 2025 08:05AM
Nov 6, 2025 08:05AM
Oct 8, 2025 08:20AM
Oct 1, 2025 04:34PM
Sep 16, 2025 08:34AM Aptevo reports 100% remission rate in AML trial cohort 3
Sep 16, 2025 08:30AM
Sep 5, 2025 09:00AM
Sep 4, 2025 08:46AM
Sep 4, 2025 08:45AM
Aug 13, 2025 08:06AM
Aug 13, 2025 08:05AM
Aug 11, 2025 10:53AM Aptevo Therapeutics (APVO) Misses Q2 EPS by 840c
Aug 11, 2025 08:05AM

477,581 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All